Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.

Lotia Farrukh I Lachenal N Adenov MM Ahmed S Algozhin Y Coutisson S Garavito ES Hewison C Holtzman D Huerga H Janmohamed A Khan PY Jacques GL Lomtadze N Melikyan N Mitnick CD Mussabekova G Osso E Perea S Putri FA Rashidov M Rich ML Sakhabutdinova Y Seung KJ Stambekova A Vásquez DV Franke MF Khan U
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Aug 22; . doi: 10.1093/cid/ciad445. Epub 2023 08 22
drug resistance outcome pregnancy treatment tuberculosis


Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.